ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
ProMIS Neurosciences (Nasdaq: PMN) has announced a private placement financing of up to $122.7 million. The deal includes an upfront $30.3 million and potential additional $92.4 million from warrant exercises. The financing involves issuing Common Share Units and Pre-Funded Units at $2.15 and $2.14 per unit, respectively. Each unit includes various warrants with different exercise prices and expiration conditions.
The funds will support the development of PMN310, ProMIS' lead antibody therapeutic for Alzheimer's disease. The financing is expected to close on July 31, 2024, subject to conditions. Notable investors include Great Point Partners, Armistice Capital, and Ally Bridge Group. Guggenheim Securities led the placement, with Ceros Financial Services and Leede Financial as additional agents.
ProMIS Neurosciences (Nasdaq: PMN) reported its Q1 2024 financial results and corporate updates. The company is progressing with its Phase 1a clinical trial of PMN310 for Alzheimer's disease (AD), expecting top-line data by mid-2024. The trial evaluates safety, tolerability, and pharmacokinetics in healthy volunteers. ProMIS also plans a Phase 1b study in H2 2024. Recent publications support PMN310’s potential. In the ALS program, PMN267 showed promising preclinical data. ProMIS selected PMN400 as a lead vaccine candidate for synucleinopathies. Financially, ProMIS reported a cash decrease to $2.5M, R&D expenses of $2.1M, G&A expenses of $1.6M, and a net loss of $3.6M.
ProMIS Neurosciences Inc. published a study highlighting the selectivity of PMN310 in targeting toxic soluble aggregates in neurodegenerative diseases such as Alzheimer’s disease. The study shows PMN310's differentiation from other amyloid-beta-directed antibodies and its potential to improve efficacy and reduce risk associated with plaque-binding therapies. PMN310 is currently undergoing Phase 1a clinical studies, with promising initial data expected in mid-2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.